Original articleClinical endoscopySafety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia
Section snippets
Study design and subjects
We performed a retrospective analysis of consecutive subjects with BE and HGD undergoing CRYO at 9 sites in the United States. Subjects with unifocal or multifocal HGD of any length were eligible. All pathological specimens demonstrating HGD were confirmed with a second histological analysis by an expert pathologist. Previous EMR or other previous endoscopic therapy was allowed if the results demonstrated no evidence of residual adenocarcinoma and residual HGD was present in the tubular
Results
A total of 98 subjects fulfilled criteria and were included in the study. Mean (SD) age was 65.4 (10) years, and 83% were male (Table 1). The baseline mean (SD) endoscopic length of BE was 5.3 (3.2) cm. Before enrollment in the study, 1 (1%) subject had undergone Nissen fundoplication. Two (2%) subjects were status post partial esophagectomy for HGD with recurrent HGD in the esophageal remnant. Fourteen (14%) subjects were status post some form of previous unsuccessful ablative therapy (2%
Discussion
Endoscopic ablation to eradicate HGD and induce reversion to squamous epithelium is a viable, esophagus-sparing treatment option for patients with BE and HGD. Multiple methods of endoscopic ablation have been developed. Each method differs in mechanism and effectiveness of ablation, side effects, and cost. Our retrospective analysis of subjects with HGD treated with CRYO at 9 institutions, the largest reported experience with this technique to date, suggests that CRYO is associated with a
References (18)
- et al.
Barrett's oesophagus
Lancet
(2009) - et al.
The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry
Am J Gastroenterol
(1999) - et al.
Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial
Gastrointest Endosc
(2005) - et al.
Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: preliminary results
Gastrointest Endosc
(1996) - et al.
Cryoablation of Barrett's esophagus: a pilot study
Gastrointest Endosc
(2005) - et al.
Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation
Hum Pathol
(2001) - et al.
Carbon dioxide (CO2) cyotherapy is a safe and effective treatment of Barrett's esophagus (BE) with HGD/intramucosal carcinoma [abstract]
Gastrointest Endosc
(2009) - et al.
An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients
Gastrointest Endosc
(2009) - et al.
Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients
Gastrointest Endosc
(1999)
Cited by (235)
An experimental study to characterise the role of multihole nozzle in adjuvant assisted cryospray
2023, International Journal of Thermal SciencesManagement of Dysplastic Barrett's Esophagus and Early Esophageal Adenocarcinoma
2022, Gastroenterology Clinics of North AmericaQuality in Barrett's Esophagus: Diagnosis and Management
2022, Techniques and Innovations in Gastrointestinal EndoscopyBarrett's Esophagus: Diagnosis, Management, and Key Updates
2021, Gastroenterology Clinics of North America
DISCLOSURE: The following authors disclosed financial relationships relevant to this publication: N.J. Shaheen: Grant from, consultant for, and advisory committee member of CSA Medical; grant from BÂRRX Medical Inc. B.D. Greenwald: Consultant for and advisory committee member of CSA Medical. J.A. Dumot: Consultant for and advisory committee member of CSA Medical. N.S. Nishioka: Research support from CSA Medical. H.C. Wolfsen: Research support from CSA Medical; research support from BÂRRX Medical Inc. K.K. Wang: Research support from CSA Medical; research support from BÂRRX Medical Inc. M.H. Johnston: Research support from CSA Medical. J.S. Barthel: Research support from CSA Medical. C.J. Lightdale: Advisory committee member of CSA Medical. All other authors disclosed no financial relationships relevant to this publication. This study was funded in part with a grant from CSA Medical, makers of the spray cryotherapy device. Dr. Peery is supported by a grant from the National Institutes of Health (T32 DK 07634). Statistical analysis and data management were also supported by a grant from the National Institutes of Health (P30 DK034987). Dr. Abrams is supported in part by a K07 award from the National Cancer Institute (CA 132892).